@ScottAdamsSays @AJA_Cortes the distinction between COVID results in ivermectin and non-ivermectin African countries was analysed by three Japanese doctors and published in medrxiv preprint earlier this year medrxiv.org/content/10.110… 
@ScottAdamsSays @AJA_Cortes 2/ their underlying data is set out in two tables collating cases, deaths and recoveries for the two groups of African countries, together with population.
@ScottAdamsSays @AJA_Cortes 3/ they reported a statistically significant difference between the two groups, but the aggregate statistics were much more interesting than mere "statistically significant differences"
@ScottAdamsSays @AJA_Cortes 4/ the population of ivermectin countries was 972MM, non-iver 357 MM. Cases (to closing date for article stats) were 707K in iver countries, 2519K in non-iver. Incidence per M was 727 in iver countries 7051 in non-iver; similarly, deaths per M in iver countries 13 per M, 186 non
@ScottAdamsSays @AJA_Cortes 5/ these numbers are based on quick collation of data in tables of Japanese doctors. But the numbers on their face are FAR FAR more impressive than anything for Remsidivir which Fauci praised to the skies as a gamechanger.
@ScottAdamsSays @AJA_Cortes 6/ it would be fairly straightforward to bring these numbers up to date to see if the results still hold.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
